OIST OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY
沖縄科学技術大学院大学

OIST Presidential Lecture

Pseudo-natural peptides, products and neobiologics for therapeutic applications



*Miura, T., Malla, T.R., Owen, C.D. et al. In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease. Nat. Chem. 15, 998–1005 (2023). https://doi.org/10.1038/s41557-023-01205-1

Mon., Dec. 4

13:30 – 15:00 B250

Macrocyclic peptides possess attractive pharmacological characteristics distinct from other well-established therapeutic molecular classes, resulting in a versatile drug modality with a unique profile of advantages. These macrocyclic peptides are accessible not only through chemical synthesis but also through ribosomal synthesis.

This lecture will discuss various screening technologies, the RaPID system, and showcase the therapeutic potential of macrocyclic peptides. It will also cover recent advancements in neobiologics development using LassoGraft technology.

Prof. Hiroaki Suga

The University of Tokyo
Winner of the 2023 Wolf Prize in Chemistry

Prof. Hiroaki Suga, with a Ph.D. from MIT, is a chemistry professor at the University of Tokyo. A recipient of numerous awards, including the 2023 Wolf Prize in Chemistry, he currently serves on Japan's Council of Science, Technology, and Innovation.

For inquiries contact ✉ **oist_president@oist.jp**